Esperion (ESPR) CLO receives new stock and option grants

Rhea-AI Filing Summary

Esperion Therapeutics Chief Legal Officer Benjamin Looker reported receiving new equity compensation. He was granted a stock option for 269,230 shares of Common Stock at an exercise price of $2.44 per share, expiring on March 13, 2036.

He also received 300,840 shares of Common Stock as a direct grant, bringing his direct Common Stock holdings to 685,056 shares after the award. The stock option award will vest over four years in equal quarterly installments, starting on June 15, 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Looker Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		300,840(1)	A	$0	685,056	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.44	03/13/2026		A		269,230		(1)	03/13/2036	Common Stock	269,230	$0	269,230	D

Explanation of Responses:

1. Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Esperion (ESPR) report for Benjamin Looker?

Benjamin Looker received equity awards, not open-market trades. He was granted a stock option for 269,230 shares at $2.44 per share and 300,840 shares of Common Stock, increasing his direct holdings to 685,056 shares after the grant.

Were the Esperion (ESPR) transactions by Benjamin Looker buys or sales?

The transactions are equity grants, not market buys or sales. Both entries are coded as awards, giving Benjamin Looker additional options and shares as compensation rather than reflecting open-market purchase or sale activity.

How many Esperion (ESPR) shares does Benjamin Looker hold after these awards?

After the transactions, Benjamin Looker holds 685,056 Common shares directly. This total reflects the addition of 300,840 newly granted shares reported in the filing, all categorized as direct ownership following the awards.

What are the key terms of Benjamin Looker’s new Esperion (ESPR) stock option?

The new option covers 269,230 shares at $2.44 per share. It is a right to buy Esperion Common Stock, with an expiration date of March 13, 2036, providing long-dated potential ownership if exercised in the future.

How does Benjamin Looker’s Esperion (ESPR) stock option vest?

The option vests over four years in equal quarterly installments. The first vesting date is June 15, 2026, after which additional portions will vest every quarter until the full 269,230-share award is vested, assuming continued service.

What is the significance of the grant price in Benjamin Looker’s Esperion (ESPR) option?

The option’s exercise price is set at $2.44 per share. This means he can only benefit economically if Esperion’s market price exceeds that level when he chooses to exercise the option before it expires in 2036.